Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Noile-Immune BiotechTSE:4893 +1.44%49 PB Ratio is 1.62 as of Jul. 23, 2026, which is 1% below its 10-year median of 1.63. GuruFocus rates TSE:4893 with a GF Score™ of 49/100 and a GF Value™ of 円4.31 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,230 Biotechnology companies, Noile-Immune Biotech ranks better than 69.11% on this metric.
The historical rank and industry rank for Noile-Immune Biotech's PB Ratio or its related term are showing as below:
TSE:4893'
s PB Ratio Range Over the Past 10 Years
Min: 1.06 Med: 1.63 Max: 4.59
Current: 1.61
During the past 6 years, Noile-Immune Biotech's highest PB Ratio was 4.59. The lowest was 1.06. And the median was 1.63.
TSE:4893's PB Ratio is ranked better than 69.11% of 1230
companies
in the Biotechnology industry
Industry Median: 2.82
vs TSE:4893: 1.61
During the past 12 months, Noile-Immune Biotech's average Book Value Per Share Growth Rate was -16.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Noile-Immune Biotech was 27.60% per year. The lowest was -4.60% per year. And the median was 2.40% per year.
Back to Basics: PB Ratio
Noile-Immune Biotech (TSE:4893) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Noile-Immune Biotech PB Ratio Related Terms
Noile-Immune Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Noile-Immune Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Noile-Immune Biotech (TSE:4893) has a PB Ratio of 1.62 as of Jul. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Noile-Immune Biotech and its competitors. This is near median its historical median of 1.63. Over the past decade, Noile-Immune Biotech's PB Ratio has ranged from 1.06 to 4.59. According to the industry distribution chart, Noile-Immune Biotech ranks #380 out of 1230 companies in the Biotechnology industry, placing it in the top 30.9%.
Is Noile-Immune Biotech's PB Ratio too high?
Noile-Immune Biotech's current PB Ratio of 1.62 is near median its 10-year median of 1.63. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 4.59. The Biotechnology industry median PB Ratio is 2.82. Noile-Immune Biotech's value of 1.62 is 42.6% below this industry median. Based on the distribution chart, Noile-Immune Biotech ranks #380 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Noile-Immune Biotech has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #380 out of 1230 companies for PB Ratio. This puts Noile-Immune Biotech in the upper half of its industry. The industry median PB Ratio is 2.82. Noile-Immune Biotech's value of 1.62 is 42.6% below this benchmark. Historically, Noile-Immune Biotech's own PB Ratio has ranged from 1.06 to 4.59 over the past decade. While the company's 10-year median is 1.63 vs. the industry median of 2.82, Noile-Immune Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noile-Immune Biotech's current PB Ratio of 1.62 is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Noile-Immune Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current PB Ratio is 1.62, which is near median its own 10-year median of 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.31, compared to a current price of 円141.00 — trading 3171.5% above its estimated fair value. The current PB Ratio is 1.62, which is near median its 10-year median of 1.63 and 42.6% below the Biotechnology industry median of 2.82. Noile-Immune Biotech's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current PB Ratio is 1.62 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円141.00 is trading 3171.5% above its estimated GF Value™ of 円4.31.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
PB Ratio: 1.62 (near median its 10-year median of 1.63)
GF Value™: 円4.31 vs. price of 円141.00 (3171.5% above fair value)
Industry Position: 42.6% below the Biotechnology median (#380 of 1230)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
49GF Score
Get the complete analysis for TSE:4893
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
